CD44+/CD24-细胞在乳腺癌组织及细胞系中的数量与分布

Objective To study the distribution and quantity of CD44VCD24- cells in breast cancer tissue and the cell lines,and as well as its correlation with the expression of various breast cancer markers and molecular subtyping of breast carcinoma.Methods The expression of CD44 / CD24,estrogen receptor,progesterone receptor,HER2,human estrogen-induced protein PS2,bcl-2 and nm23 in 60 cases of invasive ductal carcinoma of breast were studied by either single or double immunohistochemical staining.The co-expression of CD44 and CD24 in 3 breast cancer cell lines (MCF-7,MDA-MB-468,and MDA-MB- 231) was also examined.Results The quantity and distribution of CD44 + /CD24- cells varied greatly and no specific patterns were identified.The percentage of CD44 + /CD24- in breast cancer was 65%.The amount of CD44+/CD24- cells did not correlate with the age of patients,lymph node metastasis,tumor　 size,molecular subtypes and expression of various breast cancer markers in breast carcinoma.The proportion of CD44+/CD24- cells in MCF-7,MDA-MB-468,and MDA-MB-231 cell lines was < 1%,5% and > 80% ,respectively.Conclusions CD44+ /CD24- cells are demonstrated in certain breast cancer tissues and cell lines.However,there is no relationship obtained between the quantity or the distribution of these cells and the molecular subtyping or the clinicopathologic parameters in breast cancer.     

CD44+/CD24-细胞在乳腺癌组织及细胞系中的数量与分布

Objective To study the distribution and quantity of CD44VCD24- cells in breast cancer tissue and the cell lines,and as well as its correlation with the expression of various breast cancer markers and molecular subtyping of breast carcinoma.Methods The expression of CD44 / CD24,estrogen receptor,progesterone receptor,HER2,human estrogen-induced protein PS2,bcl-2 and nm23 in 60 cases of invasive ductal carcinoma of breast were studied by either single or double immunohistochemical staining.The co-expression of CD44 and CD24 in 3 breast cancer cell lines (MCF-7,MDA-MB-468,and MDA-MB- 231) was also examined.Results The quantity and distribution of CD44 + /CD24- cells varied greatly and no specific patterns were identified.The percentage of CD44 + /CD24- in breast cancer was 65%.The amount of CD44+/CD24- cells did not correlate with the age of patients,lymph node metastasis,tumor　 size,molecular subtypes and expression of various breast cancer markers in breast carcinoma.The proportion of CD44+/CD24- cells in MCF-7,MDA-MB-468,and MDA-MB-231 cell lines was < 1%,5% and > 80% ,respectively.Conclusions CD44+ /CD24- cells are demonstrated in certain breast cancer tissues and cell lines.However,there is no relationship obtained between the quantity or the distribution of these cells and the molecular subtyping or the clinicopathologic parameters in breast cancer.     

食管鳞状细胞癌组织中TPX2的表达

癌前病变组织中TPX2 mRNA阳性率分别为73.3%(16/22)、60.0%(12/18),正常食管黏膜组织中TPX2 mRNA几乎不表达,3种组织间比较,差异有统计学意义(P<0.05).食管鳞癌组织中TPX2蛋白及mRNA的表达与癌组织浸润深度及淋巴结转移有关(P均<0.05).结论:TPX2高表达可能是食管鳞癌淋巴结转移的危险因素;TPX2有望成为食管鳞癌早期诊断及判断预后的指标.     

玻璃酸钠联合氨基葡萄糖治疗膝骨性关节炎疗效观察

目的观察玻璃酸钠联合氨基葡萄糖治疗膝关节骨性关节炎的近期疗效。方法将门诊75例膝关节骨性关节炎患者随机分为治疗组45例和对照组30例,治疗组采用玻璃酸钠注射液2m l关节腔内注射,每周1次,同时口服硫酸氨基葡萄糖钾胶囊0.5g,每日2次;对照组仅口服硫酸氨基葡萄糖钾胶囊0.5g,每日2次。两组均以5周为1个疗程。结果治疗组治愈18例,显效15例,好转10例,无效2例,总有效率95.56%;对照组治愈10例,显效7例,好转6例,无效7例,总有效率76.67(。两组疗效差异具有统计学意义(P<0.05)。结论玻璃酸钠联合氨基葡萄糖治疗膝关节骨性关节炎具有较好的近期疗效,其远期疗效及作用机理有待于进一步深入研究。     

酚妥拉明与低分子肝素钙治疗肺源性心脏病心力衰竭

目的观察酚妥拉明与低分子肝素钙治疗肺源性心脏病心力衰竭的疗效。方法将76例肺源性心脏病患者随机分为观察组和对照组。对照组36例采用常规的内科治疗方法;观察组40例在对照组治疗的基础上,加用酚妥拉明与低分子肝素钙,连用7～10d后观察疗效。结果观察组的显效率和总有效率分别为72.5%和87.5%,而对照组则分别为66.7%和77.7%,观察组的疗效明显优于对照组,两者有显著性差异(P<0.05)。结论酚妥拉明与低分子肝素钙治疗肺源性心脏病心力衰竭的疗效较为显著,值得推广应用。     

维吾尔族和汉族乳腺浸润性导管癌TSP、MVD、erbB4表达的差异

目的:研究血小板反应素(Thrombospondin,TSP)、微血管标记的微血管密度(microvessel density,MVD)、erbB4蛋白3项指标在维吾尔族和汉族乳腺浸润性导管癌的表达差异。方法:收集14例维吾尔族和31例汉族乳腺浸润性导管癌(IDC)外科手术标本,采用免疫组化SP法检测TSP、MVD、erbB4蛋白表达。结果:维、汉族IDC中TSP、MVD阳性表达率差异无统计学意义(P>0.05);erbB4蛋白阳性表达率差异有统计学意义(P<0.05)。结论:erbB4基因可能促进汉族乳腺浸润性导管癌的发生、发展,具有种族特异性。但TSP、MVD表达在汉族和维吾尔族中不具有差异。     

维、汉2族乳癌组织中血小板反应素和微血管密度表达的差异

目的：探讨维吾尔族（维族）和汉族乳腺浸润性导管癌（IDC）组织中血小板反应素-1（TSP—1）蛋白和微血管密度（MVD）表达的差异。方法：选择70例汉族和70例维族IDC组织，采用免疫组化SP法，检测了TSP—1蛋白表达情况和MVD值。结果：两个民族IDC组织中TSP蛋白表达和MVD值差异均无统计学意义（P〉0．05）。结论：在维族和汉族IDC组织中，微血管的生成调控可能与种族背景无关。     

干细胞样细胞在不同乳腺癌细胞系的标记研究

目的:观察不同乳腺癌细胞系中干细胞样细胞的分布特点.方法:采用免疫细胞化学双染法,检测乳腺癌细胞系MCF-7、MDA-MB-468、MDA-MB-231中干细胞样细胞标志MUC-1/ESA、CD44/CD24的表达情况.结果:MCF-7细胞系MUC-1-/ESA+细胞的表达率为100%、CD44+/CD24-为2%:MDA-MB-468细胞系MUC-1-/ESA+细胞的表达率为35%、CD44+/CD24-为5%;MDA-MB-231细胞系MUC-1-/ESA+细胞的表达率为1%、CD44+/CD24-为85%.结论:不同乳腺癌细胞系可能具有不同的干/祖细胞体系.     

CD44v5在乳腺良恶性疾病中的表达及维汉族差异

目的探讨CD44v5在乳腺良恶性疾病中的表达情况及其在维吾尔族(维族)和汉族之间可能存在的表达差异。方法采用免疫组化S-P法检测了汉族患者的乳腺纤维腺瘤、小叶增生和维族及汉族的乳腺浸润性导管癌(IDC)3种病变中CD44v5表达情况。结果CD44v5表达率在乳腺良恶性疾病之间无统计学意义(P>0.05);IDC淋巴结转移组CD44v5表达率低于无转移组(P<0.05);在维汉族之间IDC中无统计学意义(P>0.05)。结论CD44v5可能对乳腺IDC的淋巴结转移有抑制作用,其表达在维汉族之间无统计学意义。     

CD44+/CD24-细胞在乳腺癌组织及细胞系中的数量与分布

Objective To study the distribution and quantity of CD44VCD24- cells in breast cancer tissue and the cell lines,and as well as its correlation with the expression of various breast cancer markers and molecular subtyping of breast carcinoma.Methods The expression of CD44 / CD24,estrogen receptor,progesterone receptor,HER2,human estrogen-induced protein PS2,bcl-2 and nm23 in 60 cases of invasive ductal carcinoma of breast were studied by either single or double immunohistochemical staining.The co-expression of CD44 and CD24 in 3 breast cancer cell lines (MCF-7,MDA-MB-468,and MDA-MB- 231) was also examined.Results The quantity and distribution of CD44 + /CD24- cells varied greatly and no specific patterns were identified.The percentage of CD44 + /CD24- in breast cancer was 65%.The amount of CD44+/CD24- cells did not correlate with the age of patients,lymph node metastasis,tumor　 size,molecular subtypes and expression of various breast cancer markers in breast carcinoma.The proportion of CD44+/CD24- cells in MCF-7,MDA-MB-468,and MDA-MB-231 cell lines was < 1%,5% and > 80% ,respectively.Conclusions CD44+ /CD24- cells are demonstrated in certain breast cancer tissues and cell lines.However,there is no relationship obtained between the quantity or the distribution of these cells and the molecular subtyping or the clinicopathologic parameters in breast cancer.